{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"352. Chris Kiple, CEO of Solius Labs","description":"Today, I'm joined by Chris Kiple, CEO of Solius Labs. &amp;nbsp; A decade in development, Solius\u2019s FDA-cleared UVB light therapy device personalizes dosage by skin type, aiming to replicate the benefits of sunlight while minimizing carcinogenic risk.&amp;nbsp; &amp;nbsp; In this episode, we discuss sunlight as a foundational pillar of health and longevity.&amp;nbsp; &amp;nbsp; We also cover:  Why sun avoidance is deadlier than smoking Designing a skin scanner for personalized UVB dosing Moving UVB therapy from clinical dermatology to consumer health    Subscribe to the podcast \u2192 insider.fitt.co\/podcast&amp;nbsp; Subscribe to our newsletter \u2192 insider.fitt.co\/subscribe&amp;nbsp; Follow us on LinkedIn \u2192 linkedin.com\/company\/fittinsider&amp;nbsp; &amp;nbsp; Website: www.solius.com&amp;nbsp; Instagram: https:\/\/www.instagram.com\/soliuslabs&amp;nbsp; &amp;nbsp; - &amp;nbsp; The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com&amp;nbsp; to learn more about its smart fitness ecosystem for fitness and health facilities. &amp;nbsp; Fitt Talent: https:\/\/talent.fitt.co\/&amp;nbsp; Consulting: https:\/\/consulting.fitt.co\/&amp;nbsp; Investments: https:\/\/capital.fitt.co\/&amp;nbsp; &amp;nbsp; Chapters: (00:00) Introduction (00:29) Swedish longevity study (01:20) Chris background and Solius overview (02:05) UVB light therapy foundation (04:00) 10-year development and timing (05:07) Sun exposure evolution and skin type (08:10) Solius technology and personalized dosing (09:35) Skin scanning and dosing mechanism (11:00) FDA clearance and safety focus (12:40) OTC vs. prescription positioning (14:15) Safety risk contextualization (15:42) Healthcare partnerships strategy (17:50) Dermatology focus (19:00) Orthopedic and cardiovascular applications (20:32) Longevity clinic partnerships (22:35) Swedish and UK biobank studies (26:00) Hormone production benefits (27:20) Cardiovascular and nitric oxide improvements (28:30) Microbiome diversity impact (31:15) Platform evolution and future devices (33:20) Team-building and advisory board (34:45) Listening to early users (36:40) Where to find (38:07) Conclusion ","author_name":"Fitt Insider","author_url":"https:\/\/insider.fitt.co","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42444110\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/205110200"}